Best overall response with anetumab ravtansine plus pegylated liposomal doxorubicin in all treated patients and patients categorized by mesothelin expression and prior lines of systemic therapy
| All treated patients (n=65) | High mesothelin expression and ≤3 prior lines of systemic therapy (n=19) | High mesothelin expression and >3 prior lines of systemic therapy (n=13) | |
| Best overall response, n (%) | |||
| Complete response | 1 (1.5)* | 0 | 0 |
| Partial response | 17 (26.2) | 8 (42.1) | 2 (15.4) |
| Stable disease ≥4 months | 12 (18.5) | 5 (26.3) | 4 (30.8) |
| Stable disease <4 months | 16 (24.6) | 5 (26.3) | 5 (38.5) |
| Progressive disease | 11 (16.9) | 1 (5.3) | 2 (15.4) |
| Not evaluable† | 8 (12.3) | 0 | 0 |
| Objective response rate, % (95% CI)‡ | 27.7 (17.3 to 40.2) | 42.1 (20.3 to 66.5) | 15.4 (1.9 to 45.5) |
| Disease control rate, % (95% CI)§ | 70.8 (58.2 to 81.4) | 94.3 (74.0 to 99.9) | 84.6 (54.6 to 98.1) |
*One patient with complete response had non-measurable disease with completely resolved lesions.
†Patients had no measurable lesions or follow-up assessments.
‡Proportion of patients with a complete response or partial response.
§Proportion of patients with a complete response, partial response, or stable disease.